EUVIMEDEUVIMED entdecken
Open Access

AFP-specific T cell receptors with fine-tuning affinity induce durable tumor remission in mice and acquire pan-HLA-A∗02 recognition

Chen-Song Huang, Jiajia Du, Jun Li, Ya-Hao Guo, Qingjia Yan, Shifan Wu, Xihe Chen, Tein Foong Leong, Si-Yun Chen, An-Da Zheng, Shudan Ou, Minjun Ma und 5 weitere

Molecular Therapy · 2026-05 · 34 (5) · 2666-2677

DOI: 10.1016/j.ymthe.2026.01.026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026-05. Verfasst von Chen-Song Huang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreato-Biliary Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China. Hauptthemen laut MEDLINE: alpha-Fetoproteins, Receptors, Antigen, T-Cell, HLA-A2 Antigen, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cell receptor-engineered T cell (TCR-T cell) therapies enable targeting of intracellular antigens presented by HLA molecules, addressing the limitations of solid tumors lacking surface antigens. We developed a novel alpha-fetoprotein (AFP)-specific TCR-T cell for hepatocellular carcinoma. Starting from a previously cloned AFP-specific TCR (A01) restricted by HLA-A∗02:03, we enhanced its affinity through structure-guided optimization. A single amino acid substitution in the CDR3 region of the TCR Vβ chain significantly enhanced the antigen-specific activity. This modified TCR (A01-m14) triggered robust responses in both CD4+ and CD8+ TCR-T cells, demonstrating potent efficacy against patient-derived organoids and in murine models. Notably, CD4+ and CD8+ TCR-T cells acted synergistically to sustain antitumor effects. A01-m14 TCR exhibited a favorable safety profile with no detectable off-target reactivity against the human proteome or unrelated HLA molecules. The further engineered TCR (A01-m58) was able to recognize most HLA-A∗02 subtypes, significantly expanding the eligible patient population. Meanwhile, the pan-A∗02-TCR-T cells also showed enhanced cytokine production, superior tumor cell killing, and achieved complete tumor eradication in murine models. This study developed an AFP-specific TCR-T cell with fine-tuning affinity, demonstrating remarkable preclinical efficacy and safety, alongside a sequence-optimized version with pan-HLA-A∗02 applicability, offering broader patient access and therapeutic versatility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-FetoproteinsReceptors, Antigen, T-CellHLA-A2 AntigenCarcinoma, HepatocellularLiver NeoplasmsAnimalsHumansMiceCell Line, TumorImmunotherapy, AdoptiveCD8-Positive T-LymphocytesXenograft Model Antitumor AssaysDisease Models, AnimalCD4-Positive T-Lymphocytes

Stichwörter der Autor:innen

AFPTCR-T cell therapyalpha fetoproteinhepatocellular carcinomapan-HLA recognition

Substanzen

alpha-FetoproteinsReceptors, Antigen, T-CellHLA-A2 Antigen

Autor:innen und Institutionen

  • Department of Pancreato-Biliary Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.
  • HRYZ Biotech Co., Guangzhou 510525, China.
  • Key Laboratory of Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-sen University, Guangzhou 510080, China.
  • HRYZ Biotech Co., Guangzhou 510525, China. Electronic address: chujunjun@gmail.com.
  • HRYZ Biotech Co., Guangzhou 510525, China. Electronic address: hanyy@thyx.com.

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Huang, C. S., Du, J., Li, J., Guo, Y. H., Yan, Q., Wu, S., Chen, X., Leong, T. F., Chen, S. Y., Zheng, A. D., Ou, S., Ma, M., Yang, C., Zhang, L., Zhou, X., Chu, J., & Han, Y. (2026). AFP-specific T cell receptors with fine-tuning affinity induce durable tumor remission in mice and acquire pan-HLA-A∗02 recognition. Molecular Therapy, 34(5), 2666-2677. https://doi.org/10.1016/j.ymthe.2026.01.026

Vancouver

Huang CS, Du J, Li J, Guo YH, Yan Q, Wu S, et al. AFP-specific T cell receptors with fine-tuning affinity induce durable tumor remission in mice and acquire pan-HLA-A∗02 recognition. Molecular Therapy. 2026;34(5):2666-2677. doi:10.1016/j.ymthe.2026.01.026

BibTeX
@article{Huang2026,
  author = {Huang, Chen-Song and Du, Jiajia and Li, Jun and Guo, Ya-Hao and Yan, Qingjia and Wu, Shifan and Chen, Xihe and Leong, Tein Foong and Chen, Si-Yun and Zheng, An-Da and Ou, Shudan and Ma, Minjun and Yang, Chunguang and Zhang, Lulu and Zhou, Xiangjun and Chu, Junjun and Han, Yanyan},
  title = {AFP-specific T cell receptors with fine-tuning affinity induce durable tumor remission in mice and acquire pan-HLA-A∗02 recognition},
  journal = {Molecular Therapy},
  year = {2026},
  volume = {34},
  number = {5},
  pages = {2666--2677},
  doi = {10.1016/j.ymthe.2026.01.026}
}
Kostenlos starten →